Idiopathic pulmonary fibrosis : Molecular mechanisms and potential treatment approaches
Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved..
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung function, often manifests as exertional dyspnea and cough. Symptoms result from a fibrotic process driven by alveolar epithelial cells that leads to increased migration, proliferation, and differentiation of lung fibroblasts. Ultimately, the differentiation of fibroblasts into myofibroblasts, which synthesize excessive amounts of extracellular matrix proteins, destroys the lung architecture. However, the factors that induce the fibrotic process are unclear. Diagnosis can be a difficult process; the gold standard for diagnosis is the multidisciplinary conference. Practical biomarkers are needed to improve diagnostic and prognostic accuracy. High-resolution computed tomography typically shows interstitial pneumonia with basal and peripheral honeycombing. Gas exchange and diffusion capacity are impaired. Treatments are limited, although the anti-fibrotic drugs pirfenidone and nintedanib can slow the progression of the disease. Lung transplantation is often contraindicated because of age and comorbidities, but it improves survival when successful. The incidence and prevalence of IPF has been increasing and there is an urgent need for improved therapies. This review covers the detailed cellular and molecular mechanisms underlying IPF progression as well as current treatments and cutting-edge research into new therapeutic targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Respiratory investigation - 58(2020), 5 vom: 30. Sept., Seite 320-335 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Glass, Daniel S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 27.10.2020 Date Revised 27.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.resinv.2020.04.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310677297 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310677297 | ||
| 003 | DE-627 | ||
| 005 | 20231225140616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.resinv.2020.04.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310677297 | ||
| 035 | |a (NLM)32487481 | ||
| 035 | |a (PII)S2212-5345(20)30062-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Glass, Daniel S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Idiopathic pulmonary fibrosis |b Molecular mechanisms and potential treatment approaches |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2020 | ||
| 500 | |a Date Revised 27.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung function, often manifests as exertional dyspnea and cough. Symptoms result from a fibrotic process driven by alveolar epithelial cells that leads to increased migration, proliferation, and differentiation of lung fibroblasts. Ultimately, the differentiation of fibroblasts into myofibroblasts, which synthesize excessive amounts of extracellular matrix proteins, destroys the lung architecture. However, the factors that induce the fibrotic process are unclear. Diagnosis can be a difficult process; the gold standard for diagnosis is the multidisciplinary conference. Practical biomarkers are needed to improve diagnostic and prognostic accuracy. High-resolution computed tomography typically shows interstitial pneumonia with basal and peripheral honeycombing. Gas exchange and diffusion capacity are impaired. Treatments are limited, although the anti-fibrotic drugs pirfenidone and nintedanib can slow the progression of the disease. Lung transplantation is often contraindicated because of age and comorbidities, but it improves survival when successful. The incidence and prevalence of IPF has been increasing and there is an urgent need for improved therapies. This review covers the detailed cellular and molecular mechanisms underlying IPF progression as well as current treatments and cutting-edge research into new therapeutic targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Lung transplant | |
| 650 | 4 | |a Myofibroblast | |
| 650 | 4 | |a Pirfenidone | |
| 650 | 4 | |a Pulmonary fibrosis | |
| 650 | 4 | |a Telomere | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a pirfenidone |2 NLM | |
| 650 | 7 | |a D7NLD2JX7U |2 NLM | |
| 700 | 1 | |a Grossfeld, David |e verfasserin |4 aut | |
| 700 | 1 | |a Renna, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwala, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Spiegler, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kasselman, Lora J |e verfasserin |4 aut | |
| 700 | 1 | |a Glass, Amy D |e verfasserin |4 aut | |
| 700 | 1 | |a DeLeon, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Reiss, Allison B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory investigation |d 2012 |g 58(2020), 5 vom: 30. Sept., Seite 320-335 |w (DE-627)NLM217493343 |x 2212-5353 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:5 |g day:30 |g month:09 |g pages:320-335 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.resinv.2020.04.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 5 |b 30 |c 09 |h 320-335 | ||